z-logo
Premium
The effect of cathepsin K inhibitor on osteoclastic activity compared to alendronate and enamel matrix protein
Author(s) -
Yang Wonkyung,
Ko Hyunjung,
Kim Heesun,
Kim Miri
Publication year - 2015
Publication title -
dental traumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.82
H-Index - 81
eISSN - 1600-9657
pISSN - 1600-4469
DOI - 10.1111/edt.12152
Subject(s) - cathepsin k , pharmacology , bone resorption , chemistry , prostaglandin e2 , enamel matrix derivative , mtt assay , cathepsin , cytotoxicity , alkaline phosphatase , microbiology and biotechnology , andrology , medicine , biochemistry , osteoclast , in vitro , biology , enzyme , regeneration (biology)
Background/Aim There have been several attempts to treat delayed replantation with agents that inhibit root resorption. The purpose of this study was to assess the effectiveness of cathepsin K inhibitor in inhibiting osteoclastic activity compared to that of alendronate and enamel matrix protein. Materials and methods Murine RAW 264.7 cells were cultured in the presence of the receptor activator of NF‐ kB and lipopolysaccharide, followed by treatment with odanacatib, alendronate, or Emdogain at various concentrations. After drug treatment, an MTT assay was performed to evaluate cytotoxicity, while reverse transcription polymerase chain reaction and enzyme‐linked immunosorbent assays were performed to determine the expression levels of interleukin‐1β, interleukin‐6, prostaglandin E2, and tumor necrosis factor‐α. Data were analyzed by one‐way anova and Tukey's post‐hoc test ( P  < 0.05). Results Of all tested agents, Emdogain resulted in the least cytotoxicity on RAW 264.7 cells, while 10 −9 M odanacatib had the largest suppressive effects on the expression levels of inflammatory cytokines. Conclusions Odanacatib inhibits osteoclastic activity, showing the possibility as a treatment agent for delayed replantation of avulsed teeth.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here